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INTRODUCTION
Pseudomonas aeruginosa is a Gram-negative bacteria and a ma-
jor nosocomial pathogen that also causes opportunistic infections
in immunocompromised hosts, especially patients with cystic fi-
brosis. This pathogen possesses high intrinsic antibiotic resistance
and the ability to develop resistance to multiple antimicrobial agents
(1), therefore the spread of multidrug-resistant P. aeruginosa
(MDRPA) represents a major concern in the world (2). Some of
the known mechanisms of antibiotic resistance are linked to : 1)
the impermeability across membranes and the efflux of the drug
from the cytoplasm, 2) drug inactivation and modification by en-
zymes (e.g., β - lactamases, aminoglycoside-modifying enzymes),
and 3) changes in the targets of antibiotics (3). Treatments of in-
fections provoked by antibiotic-resistant bacteria often include
cocktails of multiple antimicrobial agents such as β - lactams and
fluoroquinolones or aminoglycosides (4-6). Alternatively, com-
bining antibiotics with efflux pump inhibitors (EPIs) is considered
(7-9).
Carbapenem-resistant Enterobacteriaceae (CRE) are defined
as Enterobacteriaceae that are resistant to carbapenem-class of
antibiotics (imipenem, meropenem, doripenem, and ertapenem)
or possess a carbapenemase (10). Among the Enterobacteriaceae
genera, Enterobacter spp. (e.g., Enterobacter aerogenes, Enterobacter
cloacae), Escherichia coli, Klebsiella pneumoniae and Citrobacter
spp. are shown to be resistant to carbapenems (11-13). CRE infec-
tion causes high mortality in infected patients, placing these or-
ganisms as a major clinical problem worldwide (12-14). Currently
available treatment options for CRE are few, therefore further stud-
ies are needed to determine the appropriate treatments (14, 15).
Quorum-sensing (QS) system is a bacterial cell - to -cell com-
munication process that relies on the bacterial population density
(16). It involves small diffusible signaling molecules called autoin-
ducers, and P. aeruginosa produces two main acyl -homoserine
lactone (AHL) autoinducers ; OdDHL (3-oxo-C12 -HSL) and BHL
(C4-HSL) (16). In previous studies, Smith et al. synthesized a library
of P. aeruginosa autoinducer analogs (AIAs) of the AHL (17, 18).
AIA-1, an analog of OdDHL, was synthesized as QS autoinducer
analog, but it did not inhibit the production of QS-related virulence
factors. The aim of this study was to investigate the combination




The structure of AIA-1 is shown in Figure 1A, and Figure 1B
shows the structure of OdDHL. AIA-1 was dissolved in water to
reach a stock concentration of 32 µg mL-1 or 64 µg mL-1. Biapenem
was purchased from Meiji Seika Pharma Co., Ltd. (Tokyo, Japan).
Levofloxacin and tobramycin were purchased from Sigma-Aldrich
(St. Louis, MO, USA).
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The bacterial strains and plasmids used in this study are listed in
Table 1. The strains were incubated at 37 in lysogeny broth (LB)
or on LB agar plates. Antibiotics were used in selective media at the
following concentrations for E. coli : tetracycline 20 mg L-1, gen-
tamycin 20 mg L-1, and ampicillin 100 mg L-1, and for P. aeruginosa :
tetracycline 200 mg L-1, carbenicillin 500 mg L-1, gentamycin
200 mg L-1, and when necessary, supplemented with 10% sucrose
for conjugation experiments.
Plasmid constructions and generation of mutant strains
In order to construct an oprD in- frame deletion mutant, approxi-
mately 500 bp of the upstream and downstream regions of oprD
gene were amplified by primers (oprDup-F : 5’ -CGACTCTAGA-
GGATCACGCATTCGCCACAGACA-3’, oprDup-R : 5’ -GTCGGT-
CGATTACAGTTTCATTGTGATTGCTCCTTT-3’, oprDdown-F :
5’ -CTGTAATCGACCGACAGG-3’, oprDdown-R : 5’ -CCATGAT-
TACGAATTTGAGGAGTCAGCAGGCAA-3’) from PAO1 chromo-
somal DNA, and cloned into pEX18Gm (19) using BamHI and
EcoRI restriction sites to generate pEX18Gm-oprD. This plasmid
DNA was mobilized from E. coli S17-1 (20) into P. aeruginosa by
mating. Colonies were screened for gentamycin sensitivity and the
loss of sucrose sensitivity. For in vivo bioluminescence imaging,
miniCTX- lux plasmid was constructed by ligating SacI/BamHI-
digested miniCTX-2 (21) with SacI/BamHI fragment digested from
pXen13 (Xenogen, CA, USA), encompassing the lux operon. The
lac promoter region was amplified by PCR using pUCP18 plasmid
(22) as a template. The amplified lac promoter region and miniCTX-
lux were digested with XhoI/BamHI and ligated, resulting in
miniCTX-Plac : : lux. PAO1 ΔoprD-Plac : : lux was created by inte-
gration of miniCTX-Plac : : lux at the attB site of PAO1 ΔoprD, fol-
lowed by FLP recombinase mediated excision of the plasmid
Figure 1. (A) The structure of AIA-1, the analog of OdDHL. (B) The
structure of OdDHL, a typical autoinducer of P. aeruginosa.
Table 1 Strains and plasmids
Strains Relevant characteristics Reference
P. aeruginosa
PAO1 Wild type
PAO1 ΔoprD PAO1 in- frame deletion of oprD This study
PAO1 ΔoprD Plac : : lux One copy of the lac promoter linked to the luxCDABE gene in the attB site of the PAO1
ΔoprD chromosome
This study
TUH44 oprD : : ISPpu12, gyrA (83Thr - Ile) Clinical isolate
TUH81 nfxC - type mutant Clinical isolate
TH5 gyrA (83Thr - Ile) Clinical isolate
Carbapenem-resistant
Enterobacteriaceae
T-CRE1 Citrobacter freundii Clinical isolate
T-CRE2 Enterobacter aerogenes Clinical isolate
T-CRE3 Enterobacter aerogenes Clinical isolate
T-CRE4 Enterobacter cloacae Clinical isolate
T-CRE5 Enterobacter aerogenes Clinical isolate
E. coli
S17-1 thi endA recA hsdR 20
Chromosome : : RP4-2Tc : : Mu-Km : : Tn7
DH5α F-,Φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rK -, mK+), phoA,
supE44, λ -, thi -1, gyrA96, relA1
TaKaRa
Plasmids
miniCTX-2 Plasmid for the integration of genes into the att site of the P. aeruginosa chromosome,
TcR
21
pXen13 Cloning vector carrying the original Photorhabdus luminescens luxCDABE operon Xenogen
pUCP18 P. aeruginosa-E. coli shuttle vector 22
miniCTX-Plac : : lux One copy of the lac promoter linked to the luxCDABE gene inserted into miniCTX-2 This study
pFLP2 FLP recombinase expressing plasmid 19
pEX18Gm Broad-host -range suicide vector ; sacB, GmR 19
pEX18Gm-oprD oprD deletion suicide vector This study
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backbone (19). Colonies were screened for tetracycline and carbe-
nicillin sensitivity and the loss of sucrose sensitivity.
Susceptibility assay
The minimum inhibitory concentration (MIC) was assessed by
the standard microbroth dilution method (23). In susceptibility as-
says including both antibiotics and AIA-1 for P. aeruginosa, AIA-1
was used at concentrations of 32 µg mL-1. For CRE, AIA-1 concen-
trations ranging from 8 to 16 µg mL-1were used.
Time kill assay
PAO1 ΔoprD, TUH44, and TH5 were grown overnight in LB
medium, then the cultures were diluted 100-fold and grown to an
OD600 of 0.2 to 0.25, or approximately 2 x 108 CFU mL-1. For TUH81,
the culture was grown to stationary phase, and then, the culture
was adjusted 2 x 108 CFU mL-1. At this point, the cells were incu-
bated in the presence of antibiotics and/or AIA-1 for various peri-
ods of time. Biapenem was used at concentrations of 64 µg mL-1 for
PAO1 ΔoprD, or 128 µg mL-1 for TUH44 and TUH81. Levofloxacin
was used at a concentration of 64 µg mL-1 for TUH44 and TUH81.
Tobramycin was used at a concentration of 64 µg mL-1 for TH5.
AIA-1 was used at concentrations of 32 µg mL-1 for PAO1 ΔoprD,
TUH44 and TH5, and at a concentration of 64 µg mL-1 for TUH81.
The number of viable cells was measured by culturing the cells on
LB agar plates. By assuming that survival at time 0 was 100%, CFU
values were converted to percent survival relative to the number
of untreated cells at time zero.
Mouse infection model by biapenem-resistant P. aeruginosa and
bioluminescence imaging
In a mouse infection model experiment, neutropenic mice were
prepared by two intraperitoneally administrations of cyclophos-
phamide monohydrate to ICR mice aged 5 to 7 weeks, at 150 mg
kg-1 at day -4 and 100 mg kg-1 at day -1 from infection. Then, mice
were infected with a luminescent carbapenem-resistant strain
PAO1 ΔoprD-Plac : : lux. An inoculum containing approximately 106
CFU was injected per thigh. AIA-1 (50 mg kg-1 body weight) was
intraperitoneally administered twice (at the point of 2 and 6 hours)
in 8 hours. Two hours after the inoculum injection, mice were sub-
cutaneously administered the selected concentrations of biapenem
(12.5 mg kg-1 body weight) 4 times over a period of 8 hours. At 0,
2, 4, 6, 8 and 10 h after the inoculum injection, mice were anes-
thetized using a constant flow of 2.5% isoflurane mixed with oxy-
gen, and bioluminescence images were acquired using an IVIS
Lumina system (Caliper, Alameda, CA, USA). At 10 h, photons emit-
ted per second by mice were quantified, and thighs from infected
mice were homogenized in saline. A portion of the homogenate
was serially diluted and then spread on a nutrient agar plate to
count CFUs. Mouse infection studies were approved by the Animal
Care and Use Committee, Okayama University, Process number
OKU-2013055. All procedures were performed according to the
Policy on the Care and Use of the Laboratory Animals, Okayama
University.
RESULTS
Susceptibility assay of P. aeruginosa to antibiotics and AIA-1.
The MICs of antibiotics and AIA-1 are shown in Table 2. The
MICs of AIA-1 ranged from 128 to 512 µg mL-1, demonstrating
very weak antibacterial activity against P. aeruginosa strains. The
MICs of biapenem for PAO1 ΔoprD, TUH44 and TUH81 were 8 to
16 µg mL-1, implying intermediate- level of resistance to biapenem.
Furthermore, TUH44 and TUH81 also demonstrated intermediate
levofloxacin resistance, and TH5 displayed intermediate levoflox-
acin and tobramycin resistance. In the presence of AIA-1 at 32 µg
mL-1, the MICs of antibiotics did not change in the tested strains,
indicating that AIA-1 did not affect the susceptibility to antibiotics
in P. aeruginosa.
Characteristics of P. aeruginosa clinical isolates about antibiotic
resistance.
Since TUH44 and TUH81 demonstrated both biapenem and
levofloxacin resistance (Table 2), we investigated the potential fac-
tors underlying resistance observed in these strains. Carbapenem
resistance in P. aeruginosa is often caused by the loss or alteration
of the outer membrane porin protein OprD (24), therefore we sought
to investigate the genetic structure of the oprD gene. In TUH44,
the genome sequence analyses revealed an insertion of an approxi-
mately 3 kbp IS element (ISPpu12, GenBank Accession Number :
AY128707) within the oprD gene, resulting in the inactivation of
OprD. The major molecular mechanism of fluoroquinolone resis-
tance is mediated by mutations in the gyrA gene, which encodes
DNA gyrase enzyme (3, 24-26). Using the method of Weile et al.
(27), in TUH44 strain, we demonstrated the presence of a mutation
in the gyrA gene at position 83 (Thr-Ile, 242CT). Next, we fo-
cused on the efflux pump MexEF-OprN, which is involved in
imipenem resistance (28, 29). We used immunoblotting to detect
specific proteins such as MexE and OprD from the clinical strains.
In TUH44, OprD and MexE were not detected, however, in TUH81
the overexpression of MexE and low expression of OprD was ob-
served (data not shown), indicating that TUH81 was nfxC - type
mutant (30). Furthermore TH5 demonstrated levofloxacin resis-
tance, and had a mutation in the gyrA gene (83Thr-Ile), as observed
in TUH44.
Efficacy of combined use of AIA-1 and biapenem against carbap-
enem-resistant P. aeruginosa.
We initially performed the killing assay on PAO1 ΔoprD mutant
in the presence of AIA-1 at a concentration of 1/4 MIC (32 µg mL-1)
Table 2 Susceptibility to antibiotics and AIA-1 for P. aeruginosa
Strain
MIC (µg mL-1)





PAO1 0.5 0.5 2 128 0.5 0.5 2
PAO1ΔoprD 8 1 2 128 8 0.5 2
TUH44a 16 16 2 256 16 16 2
TUH81b 8 8 4 128 8 8 4
TH5c 2 32 16 512 4 32 16
a OprD inactivation by an IS element insertion and a mutation of gyrA gene (83Thr - Ile).
b Nfxc- type mutant (Overexpression of efflux pump MexE).
c A mutation of gyrA gene (83Thr - Ile)
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and biapenem at a concentration of 64 µg mL-1. The survival rate
after 10-h of exposure to biapenem and AIA-1 was approximately
1000-fold lower relative to the survival in the presence of biapenem
alone (Figure 2A). In clinical isolates, we performed the killing as-
says in the presence of AIA-1 at a concentration of 32 µg mL-1 and
64 µg mL-1, for TUH44 and TUH81, respectively, and biapenem at
a concentration of 128 µg mL-1. The survival rates after 24-h were
approximately 1000-fold lower with the combined use of biapenem
and AIA-1 than those with biapenem alone (Figure 2B, C). When
AIA-1 was used alone, no killing effects were observed in the tested
strains (data not shown).
Efficacy of combined use of AIA-1 and biapenem against mouse
infection model by carbapenem-resistant strain, PAO1 ΔoprD.
Next, we focused on investigating the effects of combination use
of biapenem and AIA-1 against biapenem-resistant strain in an in
vivo mouse infection model. The bioluminescence images ob-
tained in mice infected with PAO1 ΔoprD-Plac : : lux showed no
apparent therapeutic effects of the treatment with AIA-1 alone.
However, markedly stronger therapeutic effects were observed
in mice infected with the PAO1 ΔoprD-Plac : : lux when AIA-1 was
used in combination with biapenem than when biapenem alone
was administered (Figure 3A, B). These therapeutic effects were
confirmed by counting the number of surviving cells in the thigh
after 10 h. In the group of combined treatment of AIA-1 and
biapenem, the numbers of cells demonstrated the tendency to
decrease relative to the ones observed in the group of biapenem
alone (Figure 3C). These results suggested that the combination
use of biapenem and AIA-1 was efficacious in treating carbapenem-
resistant P. aeruginosa infections.
Figure 2. Time kill assays for biapenem-resistant P. aeruginosa. (A) Time kill assay for PAO1 ΔoprD in the presence of biapenem at 64 µg mL-1
and AIA-1 at 32 µg mL-1. Biapenem alone ; filled circle on the dotted line, biapenem with AIA-1 ; filled circle on the solid line. (B) Time kill assay
for TUH44 in the presence of biapenem at 128 µg mL-1 and AIA-1 at 32 µg mL-1. Biapenem alone ; filled square on the dotted line, biapenem with AIA-1 ;
filled square on the solid line. (C) Time kill assay for TUH81 in the presence of biapenem at 128 µg mL-1 and AIA-1 at 64 µg mL-1. Biapenem alone ;
filled triangle on dotted line, biapenem with AIA-1 ; filled triangle on solid line. Under the assumption that the survival at time 0 was 100%, the numbers
of CFU were converted to percentages. Experiments were performed in triplicate. Error bars, SDs for three experiments.
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Efficacy of combined use of AIA-1 and levofloxacin or tobramycin
against resistant P. aeruginosa.
We further investigated whether the observed effects of AIA-1
are also linked to additional mechanisms of antibiotic resistance.
Two carbapenem-resistant clinical isolates, TUH44 and TUH81,
additionally showed fluoroquinolone resistance (Table 2), there-
fore we performed the time kill assays for these clinical isolates
in the presence of AIA-1 at concentrations of 32 µg mL-1 and 64 µg
mL-1, for TUH44 and TUH81, respectively, and levofloxacin at a
concentration of 64 µg mL-1. Both TUH44 and TUH81, when treated
with levofloxacin and AIA-1, demonstrated the survival rates at
the 4-h time point approximately 10- fold lower than those observed
for levofloxacin alone (Figure 4A, B). TH5 strain was resistant to
tobramycin, therefore we investigated the effects of combination
use of tobramycin and AIA-1 by killing assay. The survival rate at
the 6-h time point was approximately 10- fold lower with the com-
bined use of AIA-1 and tobramycin than that with tobramycin alone
(Figure 4C).
Susceptibility assay of CRE to antibiotics and AIA-1.
Since AIA-1 enhanced the effects of antibiotics against P. aerug-
inosa resistant strains, we further addressed whether the same
effect may be observed in other bacterial species, e.g., CRE. In
CRE, the MICs of AIA-1 were 16 or 32 µg mL-1, demonstrating
intermediate antibacterial activity in comparison to that of P. aerug-
inosa (Table 3). In addition, the MICs of carbapenems decreased
by 2- to 16- fold in the presence of 1/2 MIC of AIA-1 except for T-
CRE1 (Table 3). The 1/2 MIC of AIA-1 did not affect the growth
(data not shown), suggesting that AIA-1 may affect the suscepti-
bility to antibiotics in CRE without affecting the growth rate.
Figure 3. Effects of biapenem and AIA-1 on in vivo PAO1 ΔoprD-Plac : : lux bioluminescence signals. PAO1 ΔoprD-Plac : : lux (106 CFU) was incu-
bated per thigh. Therapy was performed with biapenem alone or combined with AIA-1, or AIA-1 alone. (A) Representative in vivo bioluminescence
on color scale images of three mice thighs. (B) Bacterial counts as measured by in vivo bioluminescence (photons/second) at 10 hours. (C) Bacterial
counts as measured by CFU at 10 hours. ** ; P0.01 (Student’s t - test)
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DISCUSSION
β - lactams (e.g., carbapenems), fluoroquinolones and aminogly-
cosides are commonly used in treatment of P. aeruginosa infections
(24, 25). However, these infections are often difficult to cure be-
cause P. aeruginosa displays multiple intrinsic and acquired mecha-
nisms of antibiotic resistance (31). β - lactam resistance commonly
occurs as a result of drug inactivation by β - lactamases, target site
alterations, diminished permeability and efflux (30). The produc-
tion of β - lactamases, such as extended-spectrum β - lactamases
(ESBLs) or metallo-β - lactamases, is a major mechanism of β - lactam
resistance in Gram-negative bacteria (30). However in P. aerugi-
nosa, carbapenem resistance is mostly related to the loss of OprD
and more rarely to carbapenemases (32). An outer membrane pro-
tein OprD is a substrate-specific outer membrane porin that facili-
tates the uptake of carbapenem antibiotics (33), and the loss of
OprD significantly reduces the susceptibility to carbapenems (34).
Our observations suggest that a mutation in the oprD gene in PAO1
ΔoprD mutant and oprD- inactivated clinical isolate TUH44, re-
sulted in increased biapenem resistance (Table 2). Combination
of AIA-1 and biapenem was more efficacious against these oprD
mutants than treatment with biapenem alone, not only in vitro
(Figure 2A, B) but also in vivomouse infection model (Figure 3).
P. aeruginosa has 12 resistance-nodulation-division (RND) sys-
tems (35, 36), whereof a set of four RND pumps contributes most
significantly to antibiotic resistance : MexAB-OprM, MexCD-OprJ,
Figure 4. Time kill assays for levofloxacin - and tobramycin-resistant P. aeruginosa. (A) Time kill assay for TUH44 in the presence of levofloxacin
at 64 µg mL-1 and AIA-1 at 32 µg mL-1. Levofloxacin alone ; filled square on the dotted line, levofloxacin with AIA-1 ; filled square on the solid line.
(B) Time kill assay for TUH81 in the presence of levofloxacin at 64 µg mL-1 and AIA-1 at 64 µg mL-1. Levofloxacin alone ; filled triangle on the dot-
ted line, levofloxacin with AIA-1 ; filled triangle on the solid line. (C) Time kill assay for TH5 on the presence of tobramycin at 64 µg mL-1 and AIA-1
at 32 µg mL-1. Tobramycin alone ; open circle on dotted line, tobramycin with AIA-1 ; open circle on solid line. Under the assumption that the sur-
vival at time 0 was 100%, the numbers of CFU were converted to percentages. The experiments were performed in triplicate. Error bars, SDs for
three experiments.
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MexEF-OprN and MexXY-OprM (36). Strains that overexpress
MexEF-OprN, known as nfxC - type mutants, exhibit resistance to
fluoroquinolones and chloramphenicol (28, 29, 35), and nfxC - type
mutant additionally displays imipenem resistance because of a
transcriptional activator MexT, which positively regulates the ex-
pression of MexEF-OprN, and represses the expression of oprD
gene (1, 24, 37, 38). To establish the effect of AIA-1 on the strain
overexpressing MexEF-OprN, we performed the killing assay
using a clinical isolate TUH81, an nfxC - type mutant. In the killing
assays, for all strains except TUH81, the logarithmic phase cultures
were used, however MexE is not expressed during the logarithmic
phase (38). Therefore, for TUH81, the stationary phase cultures
adjusted to approximately 2 x 108 CFU mL-1 were used. The com-
bination use of AIA-1 and biapenem also showed stronger efficacy
against TUH81 than the use of biapenem alone (Figure 2C). These
results suggested that AIA-1 enhanced biapenem activity and the
combination use was more efficacious against carbapenem-resis-
tant P. aeruginosa than biapenem alone.
Fluoroquinolone resistance is predominantly mediated by mu-
tations in the DNA gyrase and topoisomerase IV enzymes that are
the targets for fluoroquinolones (24, 39). Previous studies reported
that the main mechanism of fluoroquinolone resistance is medi-
ated through mutations in GyrA (25, 26). Alternatively, the above-
mentioned four efflux systems which are the members of the RND
family are known to adjust their function to fluoroquinolones, and
these efflux systems have been involved in fluoroquinolone resis-
tance in clinical isolates (40). TUH44 and TUH81 showed the re-
sistance to levofloxacin because of a mutation in the gyrA gene and
the overexpression of the efflux pump MexEF-OprN, respectively.
The combination use of AIA-1 and levofloxacin demonstrated more
pronounced decrease in the survival rates for both TUH44 and
TUH81 than those of levofloxacin alone (Figure 4A, B). This ob-
servation indicated that AIA-1 in combination with levofloxacin
also affects the clinical isolates which express fluoroquinolone
resistance.
The mechanisms of aminoglycoside resistance include outer
membrane impermeability, active efflux pump and enzymatic modi-
fication of the drug (24, 32, 41). In P. aeruginosa, the most common
aminoglycoside-resistance mechanism is enzymatic modification
of the drug by aminoglycoside-modifying enzymes (AMEs) and
16s rRNA methylases, leading to high level of resistance (32). In
addition to the mechanism described above, the overexpression
of efflux pump MexXY often causes aminoglycoside-resistance
in clinical isolate (42), and this efflux pump also accommodates
fluoroquinolones (28, 42). A clinical isolate used in this study,
TH5, showed intermediate tobramycin and fluoroquinolone resis-
tance (Table 2), suggesting that aminoglycoside-resistance of this
strain was not caused by AMEs or 16s rRNA methylases but by
overexpression of MexXY. In the killing assay for TH5, combina-
tion of AIA-1 and tobramycin produced a decrease in the survival
in comparison to tobramycin alone (Figure 4C).
In this study we have presented a new compound, AIA-1, an ana-
log of P. aeruginosa QS autoinducer, which enhanced antibacterial
effect of biapenem in in vitro time kill assay and in vivo mouse in-
fection model against carbapenem-resistant strains (Figure 2, 3).
In addition, this compound enhanced antibacterial effect of levoflox-
acin and tobramycin against fluoroquinolone- and aminoglycoside-
resistant clinical isolates (Figure 4). Although AIA-1 is the analog
of QS autoinducer, this compound does not inhibit the production
of QS-related virulence factors such as elastase and pyocyanin
(data not shown), suggesting that the effects of AIA-1 are not
mediated through inhibition of QS system. It was reported previ-
ously that the efflux pump inhibitors (EPIs) increased bacterial
susceptibility to antibiotics when used in combination with antibi-
otics (7-9). We hypothesized that if AIA-1 acts on EPIs, the MICs
of antibiotics would decrease. However, our results show that AIA-1
did not change the MICs (Table 2), implying that AIA-1 probably
exerts its effect by affecting the mechanism of antibiotic tolerance
in P. aeruginosa.
Antibiotic tolerance is the ability of bacteria to survive but not
grow under the stress of antibiotics (43). It is not caused by a gene
mutation but rather by the presence of a dormant phenotypic
variation of gene expression, referred to as persisters (44). Few
studies have examined the compounds which decrease antibiotic
tolerance, and herein we propose that AIA-1 can serve as a new
type of drug that inhibits antibiotic-resistant P. aeruginosa.
In carbapenem-resistant Enterobacteriacae, the addition of AIA-1
produced an increase in the susceptibility to antibiotics (Table 3).
Few treatment options are currently available for CRE infections
(14, 15), and this observation additionally suggests that AIA-1 may
be a new type of drug for treatment of infections caused by CRE.
CONCLUSION
The results presented in this study indicate that a new compound
AIA-1, which is an analog of P. aeruginosa QS autoinducer, en-
hances the antibacterial activity of antibiotics against antibiotic-
resistant strains by promoting a decrease in antibiotic tolerance
in P. aeruginosa. On the other hand, AIA-1 also increased the sus-
ceptibility of CRE to antibiotics.




BIPM IPM LVFX TOB AIA-1
T-CRE1
0 0.13 1 0.25 8 16
8 0.06 1 0.25 8 
T-CRE2
0 1 2 1 64 32
16 0.06 0.5 0.25 64 
T-CRE3
0 1 1 0.06 16 32
16 0.25 0.5 0.03 4 
T-CRE4
0 0.06 0.5 0.06 8 32
16 0.03 0.03 0.03 0.03 
T-CRE5
0 1 2 0.13 16 32
16 0.06 0.25 0.03 4 
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